Search

Lei Yao

Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )

Most Active Art Unit
1642
Art Unit(s)
1642
Total Applications
1328
Issued Applications
662
Pending Applications
127
Abandoned Applications
552

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 12227675 [patent_doc_number] => 09914909 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-13 [patent_title] => 'Costimulatory chimeric antigen receptor T cells targeting IL13Rα2' [patent_app_type] => utility [patent_app_number] => 15/167869 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 62 [patent_no_of_words] => 12669 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15167869 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/167869
Costimulatory chimeric antigen receptor T cells targeting IL13Rα2 May 26, 2016 Issued
Array ( [id] => 13125723 [patent_doc_number] => 10080776 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-25 [patent_title] => Molecular marker for cancer stem cell [patent_app_type] => utility [patent_app_number] => 15/162833 [patent_app_country] => US [patent_app_date] => 2016-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 34 [patent_no_of_words] => 14837 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15162833 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/162833
Molecular marker for cancer stem cell May 23, 2016 Issued
Array ( [id] => 11061998 [patent_doc_number] => 20160258960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'DETECTION OF CANCER BY ELEVATED LEVELS OF BCL-2' [patent_app_type] => utility [patent_app_number] => 15/160649 [patent_app_country] => US [patent_app_date] => 2016-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 21166 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15160649 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/160649
DETECTION OF CANCER BY ELEVATED LEVELS OF BCL-2 May 19, 2016 Abandoned
Array ( [id] => 13590035 [patent_doc_number] => 20180346566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => METHODS AND COMPOSITIONS RELATING TO ANTI-TMIGD1/IGPR-2 [patent_app_type] => utility [patent_app_number] => 15/572263 [patent_app_country] => US [patent_app_date] => 2016-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33726 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15572263 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/572263
METHODS AND COMPOSITIONS RELATING TO ANTI-TMIGD1/IGPR-2 May 18, 2016 Abandoned
Array ( [id] => 13360027 [patent_doc_number] => 20180231553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => COMPOSITION FOR ANTICANCER ADJUVANT COMPRISING RIP3 EXPRESSION PROMOTER AS ACTIVE INGREDIENT, METHOD FOR SCREENING ANTICANCER ADJUVANT WHICH PROMOTES RIP3 EXPRESSION AND ENHANCES SENSITIVITY OF ANTICANCER AGENT, AND METHOD FOR MONITORING SENSITIVITY OF ANTICANCER AGENT [patent_app_type] => utility [patent_app_number] => 15/750421 [patent_app_country] => US [patent_app_date] => 2016-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750421 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/750421
Composition for anticancer adjuvant comprising RIP3 expression promoter as active ingredient, method for screening anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of anticancer agent, and method for monitoring sensitivity of anticancer agent May 6, 2016 Issued
Array ( [id] => 11529931 [patent_doc_number] => 20170089909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-30 [patent_title] => 'METHODS AND COMPOSITIONS FOR ASSAYING BLOOD LEVELS OF LEGUMAIN' [patent_app_type] => utility [patent_app_number] => 15/146179 [patent_app_country] => US [patent_app_date] => 2016-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11653 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15146179 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/146179
METHODS AND COMPOSITIONS FOR ASSAYING BLOOD LEVELS OF LEGUMAIN May 3, 2016 Abandoned
Array ( [id] => 16499875 [patent_doc_number] => 10865250 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => Anti-cancer fusion polypeptide [patent_app_type] => utility [patent_app_number] => 15/571561 [patent_app_country] => US [patent_app_date] => 2016-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 27901 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571561 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/571561
Anti-cancer fusion polypeptide May 3, 2016 Issued
Array ( [id] => 13343653 [patent_doc_number] => 20180223366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => DIAGNOSTIC, PREDICTIVE AND PROGNOSTIC TESTING FOR CANCER [patent_app_type] => utility [patent_app_number] => 15/141908 [patent_app_country] => US [patent_app_date] => 2016-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16997 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15141908 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/141908
DIAGNOSTIC, PREDICTIVE AND PROGNOSTIC TESTING FOR CANCER Apr 28, 2016 Abandoned
Array ( [id] => 12603411 [patent_doc_number] => 20180092967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => IMMUNITY-INDUCING AGENT [patent_app_type] => utility [patent_app_number] => 15/567448 [patent_app_country] => US [patent_app_date] => 2016-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15567448 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/567448
IMMUNITY-INDUCING AGENT Apr 27, 2016 Abandoned
Array ( [id] => 14808349 [patent_doc_number] => 20190270784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-05 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/305686 [patent_app_country] => US [patent_app_date] => 2016-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305686 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/305686
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers Apr 21, 2016 Issued
Array ( [id] => 11120710 [patent_doc_number] => 20160317683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'Therapeutic Agents and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/135028 [patent_app_country] => US [patent_app_date] => 2016-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 18999 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15135028 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/135028
Therapeutic Agents and Uses Thereof Apr 20, 2016 Abandoned
Array ( [id] => 11023696 [patent_doc_number] => 20160220651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'IMMUNOGENIC TUMOR ASSOCIATED STROMAL CELL ANTIGEN PEPTIDES AND METHODS OF THEIR USE' [patent_app_type] => utility [patent_app_number] => 15/133038 [patent_app_country] => US [patent_app_date] => 2016-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 45696 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15133038 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/133038
Immunogenic tumor associated stromal cell antigen peptides and methods of their use Apr 18, 2016 Issued
Array ( [id] => 16956051 [patent_doc_number] => 11059893 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Humanized anti-AXL antibodies [patent_app_type] => utility [patent_app_number] => 15/566635 [patent_app_country] => US [patent_app_date] => 2016-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 2 [patent_no_of_words] => 15379 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15566635 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/566635
Humanized anti-AXL antibodies Apr 14, 2016 Issued
Array ( [id] => 11077151 [patent_doc_number] => 20160274114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'METHODS FOR DIAGNOSING CANCER AND DETERMINING THE OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL OF CANCER PATIENTS' [patent_app_type] => utility [patent_app_number] => 15/089770 [patent_app_country] => US [patent_app_date] => 2016-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 11213 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15089770 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/089770
METHODS FOR DIAGNOSING CANCER AND DETERMINING THE OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL OF CANCER PATIENTS Apr 3, 2016 Abandoned
Array ( [id] => 12746656 [patent_doc_number] => 20180140719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => SELF ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY [patent_app_type] => utility [patent_app_number] => 15/563339 [patent_app_country] => US [patent_app_date] => 2016-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15563339 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/563339
SELF ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY Mar 30, 2016 Abandoned
Array ( [id] => 11094027 [patent_doc_number] => 20160290995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'METHODS OF SELECTING AKT AGONISTS OR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/085757 [patent_app_country] => US [patent_app_date] => 2016-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 20458 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15085757 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/085757
METHODS OF SELECTING AKT AGONISTS OR ANTAGONISTS Mar 29, 2016 Abandoned
Array ( [id] => 12641301 [patent_doc_number] => 20180105598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => ANTI-CD133 MONOCLONAL ANTIBODIES AND RELATED COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 15/561403 [patent_app_country] => US [patent_app_date] => 2016-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561403 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/561403
Anti-CD133 monoclonal antibodies and related compositions and methods Mar 27, 2016 Issued
Array ( [id] => 12259404 [patent_doc_number] => 20180078599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'METHODS AND MATERIALS FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/562136 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 7904 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15562136 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/562136
METHODS AND MATERIALS FOR TREATING CANCER Mar 24, 2016 Abandoned
Array ( [id] => 11401747 [patent_doc_number] => 20170022286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'MEDICAL USES OF CRTAM AGONISTS' [patent_app_type] => utility [patent_app_number] => 15/078901 [patent_app_country] => US [patent_app_date] => 2016-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14472 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15078901 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/078901
MEDICAL USES OF CRTAM AGONISTS Mar 22, 2016 Abandoned
Array ( [id] => 11075757 [patent_doc_number] => 20160272721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'ANTIBODY SPECIFIC TO THE AIMP2-DX2' [patent_app_type] => utility [patent_app_number] => 15/074498 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 29193 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15074498 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/074498
Antibody specific to the AIMP2-DX2 Mar 17, 2016 Issued
Menu